Pediatric Grand Rounds Archived Webcasts

Optimizing Antibiotic Dosing in the Era of Emerging Bacterial Resistance

Recorded December 14, 2007 at 12:30 PM

Presented by:
Joseph L. Kuti, PharmD,
Associate Director, Clinical and Economic Studies, Hartford Hospital Center for Anti-Infective Research and Development, Hartford, CT

CME credit is no longer available for this program

This program is presented for educational purposes only and is no longer available for CME credit.

Disclosure: Dr. Kuti currently serves on the advisory boards/panels of AstraZeneca, Elan, and Pfizer; as a consultant to AstraZeneca, Elan, Pfizer, and Wyeth; receives grants/research support from AstraZeneca, Pfizer, and Wyeth; and serves on the speaker’s bureaus of AstraZeneca, Elan, Pfizer, Merck and Wyeth. He intends to discuss the increased dosages as well as varied infusion times for cefepime, imipenem, ciprofloxacin, levofloxacin, meropenem, piperacillin / tazobactam and fluoroquinolones in his presentation.

Clinical Content Reviewer: Juan Dumois, MD

Learning Objectives: As a result of attending this presentation, participants will be able to:

  • Assess emerging trends in gram-positive and gram-negative resistance to antibiotics
  • Describe antibiotic pharmaco-dynamic concepts and how they can be applied to current antibiotic dosing strategies to optimize clinical outcomes

Commercial Support: No

Minimum System Requirements

While the presentations may be viewable on systems that don't meet these criteria, we recommend that you use a computer that meets the following standards:

  • Broadband internet access (DSL, Cable, T1, Wi-fi)
  • Speakers or Headphones
Windows 2000, XP, or Vista
Mac OS Version - OS X
  • Browser Requirements: Internet Explorer 5.2.3 or later for Mac OS X, Safari 1.0.3 or later (Safari 1.2.4 & above recommended), Firefox 1.0 or later
  • Media Player Requirements: Windows Media Player for Mac OS X
Mac OS Version - OS 9

Troubleshooting Tips